A detailed history of Two Sigma Investments, LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Two Sigma Investments, LP holds 54,913 shares of ADCT stock, worth $191,097. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,913
Holding current value
$191,097
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.66 - $5.29 $91,155 - $290,489
54,913 New
54,913 $246,000
Q1 2023

May 15, 2023

BUY
$1.92 - $5.45 $324,347 - $920,673
168,931 Added 307.73%
223,827 $436,000
Q4 2022

Feb 14, 2023

BUY
$2.87 - $5.24 $157,551 - $287,655
54,896 New
54,896 $210,000
Q1 2021

May 17, 2021

SELL
$22.75 - $34.05 $500,431 - $748,997
-21,997 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.26 - $38.02 $555,644 - $836,325
21,997 New
21,997 $704,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $270M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.